Fig. 1.
MTS assays determining relative cell viabilities (in %) for RCC4 and 786-O cells treated with MF (a, b), SUT (c, d), and AX (e, f) for 120 h compared to untreated cells. IC50 values were calculated by using linear regression modeling.
MTS assays determining relative cell viabilities (in %) for RCC4 and 786-O cells treated with MF (a, b), SUT (c, d), and AX (e, f) for 120 h compared to untreated cells. IC50 values were calculated by using linear regression modeling.
